

Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2020.

Rs. in Crores

	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Revenue from Operations	1,341.32	1,206.83	948.91	4,605.75
2	Other Income	0.32	0.89	3.29	4.94
3	Total Income	1,341.64	1,207.72	952.20	4,610.69
4	Expenses				
	(a) Cost of Materials consumed	257.24	273.83	232.01	979.05
	(b) Purchase of stock-in-trade	49.26	34.99	81.97	270.93
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	31.27	(44.93)	(109.58)	(210.59)
	(d) Employee benefits expense	275.36	246.92	214.87	906.44
	(e) Finance Costs	6.67	7.75	4.98	27.16
	(f) Depreciation & Amortization Expense	41.50	44.14	35.40	157.32
	(g) Other Expenses	320.83	368.50	304.73	1,436.89
	Total Expenses	982.13	931.20	764.37	3,567.22
5	Profit before exceptional items and tax	359.50	276.52	187.82	1,043.47
6	Less : Exceptional Items				
	Expenses	-	46.28	32.79	79.06
	Incomes	-	(35.42)	-	(35.42)
7	Profit before tax	359.50	265.66	155.04	999.82
8	Tax Expense				
	(i) Current Tax	67.11	47.29	38.59	204.57
	(ii) Deferred Tax	(0.34)	15.94	(2.63)	(4.30)
	(iii) Short / (Excess) Tax Provision	-	(1.09)	-	(1.09)
9	Profit for the Period before Share of Profit / (Loss) of Associates and Joint Ventures	292.73	203.52	119.08	800.64
10	Share of Profit / (Loss) of Associates & Joint Venture	0.45	(0.07)	0.41	0.05
11	Net Profit after taxes and Share of Profit / (Loss) of Associates and Joint Ventures but before non-controlling interests	293.18	203.45	119.49	800.70
12	Non-controlling interests	8.28	21.18	4.24	28.12
13	Net Profit after taxes, non-controlling interests and share of Profit / (Loss) of Associates and Joint Ventures	301.46	224.63	123.72	828.82
14	Other Comprehensive Income				
A	(i) Items that will not be reclassified to profit / (loss)	(6.58)	(7.34)	(4.76)	(11.42)
	(ii) Income tax relating to items that will not be reclassified to profit / (loss)	1.14	1.26	1.02	1.97
B	(i) Items that will be reclassified to profit / (loss)	(0.28)	3.51	1.44	7.64
	Total Other Comprehensive Income (A+B)	(5.72)	(2.58)	(2.30)	(1.82)
15	Total Comprehensive Income for the period (11+14)	287.46	200.87	117.19	798.88
	Attributable to:				
	- Non-controlling interests	(8.30)	(21.20)	(4.24)	(28.17)
	- Owners of the Company	295.76	222.08	121.43	827.05
16	Earnings per share - Basic & Diluted (in Rs.)	15.99	11.92	6.56	43.97
17	Paid up Equity Share Capital (Face Value of Rs 2/- each)	37.70	37.70	37.70	37.70
18	Other Equity				3,181.71

Notes :

- 1 The above consolidated results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 As additional information to investors, the Research and Development Expenses are provided here under:
Rs. in Crores
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period.

Particulars	Quarter Ended			Year Ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
Research and Development	142.61	185.00	140.29	644.82

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 22nd July, 2020

Chirayu Amin
Chairman and CEO

Visit us at www.alembicpharmaceuticals.com

Statement of Standalone Unaudited Financial Results for the quarter ended 30th June, 2020.

Rs. in Crores

	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Revenue from Operations	1,258.43	1,048.56	896.74	4,132.55
2	Other Income	0.16	131.01	3.18	134.75
3	Total Income	1,258.59	1,179.57	899.92	4,267.31
4	Expenses				
	(a) Cost of Materials consumed	256.93	273.30	232.01	978.13
	(b) Purchase of stock-in-trade	47.99	54.01	62.13	244.26
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	37.85	(78.69)	(58.75)	(176.50)
	(d) Employee benefits expense	249.37	204.47	195.49	806.37
	(e) Finance Costs	6.09	6.97	4.66	25.19
	(f) Depreciation & Amortization Expense	35.84	36.35	32.50	135.67
	(g) Other Expenses	242.93	299.19	241.09	1,077.40
	Total Expenses	877.02	795.61	709.11	3,090.51
5	Profit before exceptional items and tax	381.57	383.96	190.80	1,176.79
6	Less : Exceptional Expense	-	10.00	-	10.00
7	Profit before tax	381.57	373.96	190.80	1,166.79
8	Tax Expense				
	(i) Current Tax	62.94	60.74	35.58	198.48
	(ii) Short /(Excess) Tax Provision	-	(1.09)	-	(1.09)
9	Net profit after tax for the period	318.64	314.30	155.22	969.40
10	Other Comprehensive Income				
	(i) Items that will not be reclassified to profit / (loss)	(6.55)	(7.31)	(4.75)	(11.30)
	(ii) Income tax relating to items that will not be reclassified to profit / (loss)	1.14	1.28	1.02	1.98
11	Total Comprehensive Income for the period	313.23	308.27	151.49	960.08
12	Earnings per share - Basic & Diluted (in Rs.)	16.90	16.67	8.23	51.42
13	Paid up Equity Share Capital (Face Value of Rs 2/- each)	37.70	37.70	37.70	37.70
14	Other Equity				3,308.32

Notes :

- 1 The above standalone results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 As additional information to investors, the Research and Development Expenses are provided here under:

Particulars	Quarter Ended			Rs. in Crores
	30.06.2020	31.03.2020	30.06.2019	Year Ended 31.03.2020
Research and Development	128.46	183.49	121.25	573.67

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period.

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 22nd July, 2020

Chirayu Amin
Chairman and CEO

Visit us at www.alembicpharmaceuticals.com